New cancer drug JS207 enters first human tests

NCT ID NCT06022250

Ongoing Disease control Sponsor: Shanghai Junshi Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called JS207 in about 98 people with advanced cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also look for any signs that the drug is shrinking tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JS207 (a drug given by intravenous infusion)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced cancers that have not responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 98 participants, so the drug may prove unsafe or ineffective. Side effects are unknown and could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANT TUMOR

Contacts and locations

Locations

Affiliated Cancer Hospital of Shandong First Medical University

Jinan, Shandong, 250117, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.